Created at	Source	Raw Value	Validated value
Oct. 26, 2020, 11:31 p.m.	usa	Number of Participants With any Adverse Events(AEs) as assessed by DAIDS;Number of Participants that achieve Virologic Clearance after oral administration of EIDD-2801;Number of Participants With any Serious Adverse Events(SAEs) as assessed by DAIDS	Number of Participants With any Adverse Events(AEs) as assessed by DAIDS;Number of Participants that achieve Virologic Clearance after oral administration of EIDD-2801;Number of Participants With any Serious Adverse Events(SAEs) as assessed by DAIDS